The mission of the Rutgers Cancer Institute of New Jersey (CINJ) is to reduce the burden of cancer by advancing cancer research, prevention, screening, education and care for one of the nation?s most diverse and densely populated states, as well as the broader nation. To accomplish this mission, the CINJ Director, Steven K. Libutti, MD, works closely with the rest of the CINJ Senior Leadership team, which includes the Deputy Director (Eileen White), and Associate Directors for Clinical Research (Howard S. Hochster), Basic Research (Eileen White), Cancer Prevention, Control and Population Research (Sharon L. Manne), Translational Research (Shridar Ganesan), Consortium Research (Yibin Kang), Research and Education Affairs (Edmund C. Lattime), Administration and Planning (Linda L. Tanzer) and Community Outreach and Engagement (new, Manne interim). Implementation of a five-year Strategic Plan (2015-2020) was underway at the time of Libutti?s arrival in 2017; the plan was re-assessed modified to represent the new Director?s vision. The Internal Advisory Board (includes the Chancellor, Deans and other leaders at Rutgers and Princeton Universities) and the External Advisory Board reviewed these proposed modifications and provided critical input and guidance. This oversight and leadership structure proved its effectiveness with the transition to a new Director; the major goals of the strategic plan were affirmed, with significant and sustained progress made toward accomplishing them, and new initiatives important to the Director?s vision were seamlessly integrated. Despite the change in Directorship, senior leaders did not lose momentum and achieved important strategic accomplishments, including: restructured and enhanced precision medicine initiative; recruitment of a new Associate Director for Clinical Research; increased accruals to interventional studies; creation of an Office of Community Outreach and Engagement and launch of a search for an Associate Director to oversee these efforts; expansion of the Metabolomics shared resource (jointly managed with Princeton University) and launch of two new developing shared resources for Small Molecule Screening (with Princeton) and Immune Monitoring; expansion of educational programs and successful management of major statewide retreats and conferences; launch of a new colon and lung cancer screening initiative for underserved regions of CINJ?s catchment area; and enhancement and strengthening of the consortium with Princeton University through the creation and appointment of an Associate Director for Consortium Research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA072720-20
Application #
9632910
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-03-07
Budget End
2020-02-29
Support Year
20
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Warner, Wayne A; Lee, Tammy Y; Fang, Fang et al. (2018) The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes Control 29:685-697
Zhao, Yuhan; Wu, Lihua; Yue, Xuetian et al. (2018) A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife 7:
Deek, Matthew P; Kim, Sinae; Ahmed, Inaya et al. (2018) Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol 41:362-366
O'Malley, Denalee; Dewan, Asa A; Ohman-Strickland, Pamela A et al. (2018) Determinants of patient activation in a community sample of breast and prostate cancer survivors. Psychooncology 27:132-140
Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103
Jang, Thomas L; Patel, Neal; Faiena, Izak et al. (2018) Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 124:4010-4022
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803
Patrizii, Michele; Bartucci, Monica; Pine, Sharon R et al. (2018) Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol 8:23
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
CeliĆ -Terrassa, Toni; Bastian, Caleb; Liu, Daniel et al. (2018) Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nat Commun 9:5005

Showing the most recent 10 out of 775 publications